Overview

Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)

Status:
Completed

Trial end date:
2006-05-01

Target enrollment:

Participant gender:

Summary

The objectives of this study are to characterize the safety, tolerability and pharmacokinetics of pegaptanib when given as 1 or 3mg/eye intravitreous injections every 6 weeks for 54 weeks in patients with subfoveal choroidal neovascularization (CNV) secondary to AMD.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Eyetech Pharmaceuticals

Collaborator:

Pfizer